scholarly journals Subretinal Neovascular Membrane in Wet Age-Related Macular Degeneration Managed With Intravitreal Ranibizumab

Cureus ◽  
2021 ◽  
Author(s):  
Tanishq S Sharma ◽  
Shashikant M Sharma
Keyword(s):  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Intravitreal Ranibizumab ◽  
Age Related ◽  
Subretinal Neovascular Membrane

Can Intravitreal Ranibizumab Alter Retrobulbar Circulation in Eyes with Age-Related Macular Degeneration?

2013 ◽  
Vol 29 (8) ◽  
pp. 723-727 ◽  
Author(s):  
Kemal Yuksel ◽  
Hasan Altinkaynak ◽  
Adnan Kina ◽  
Necip Kara ◽  
Ahmet Taylan Yazici ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Intravitreal Ranibizumab ◽  
Age Related

scholarly journals Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration [Corrigendum]

2016 ◽  
pp. 775
Author(s):  
Katarzyna Michalska-Malecka ◽  
Adam Kabiesz ◽  
Małgorzata Kimsa ◽  
Barbara Strzałka-Mrozik ◽  
Maria Formińska-Kapuścik ◽  
...  
Keyword(s):  
Gene Expression ◽  
Macular Degeneration ◽  
Gene Expression Profile ◽  
Expression Profile ◽  
Age Related Macular Degeneration ◽  
Intravitreal Ranibizumab ◽  
Age Related

Comparison of the Effectiveness and Prognostic Factors of Intravitreal Ranibizumab between Typical Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy over 24 Months of Follow-Up

2015 ◽  
Vol 234 (1) ◽  
pp. 33-39 ◽  
Author(s):  
Wataru Matsumiya ◽  
Shigeru Honda ◽  
Keiko Otsuka ◽  
Akiko Miki ◽  
Takayuki Nagai ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Polypoidal Choroidal Vasculopathy ◽  
Age Related Macular Degeneration ◽  
Morphological Parameters ◽  
Intravitreal Ranibizumab ◽  
Corrected Visual Acuity ◽  
Age Related ◽  
The Mean ◽  
Choroidal Vasculopathy

Purpose: To compare the response to ranibizumab between patients with typical neovascular age-related macular degeneration (tAMD) and those with polypoidal choroidal vasculopathy (PCV), and to determine the predictors for the outcomes. Methods: Fifty-nine eyes from 59 consecutive patients (tAMD: 27 eyes, PCV: 32 eyes) were treated with three monthly ranibizumab injections followed by as-needed retreatment. Best-corrected visual acuity (BCVA) and morphological parameters were evaluated over 24 months of follow-up. Results: The mean BCVA in tAMD and PCV patients was significantly improved at 3 months (-0.22 and -0.09 logMAR units, respectively). The improvement in BCVA was sustained up to 24 months in tAMD (p = 0.01) but not in PCV patients. The significant predictor for good response to ranibizumab in tAMD patients was the improvement of BCVA at 3 months, whereas that in PCV patients was the anatomical resolution at 3 months. Conclusions: Ranibizumab is an effective therapy for tAMD and PCV over 24 months. The predictors for good outcome might be different between tAMD and PCV.

scholarly journals Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration

2016 ◽  
pp. 357 ◽  
Author(s):  
Katarzyna Michalska-Malecka ◽  
Adam Kabiesz ◽  
Małgorzata Kimsa ◽  
Barbara Strzałka-Mrozik ◽  
Maria Formińska-Kapuścik ◽  
...  
Keyword(s):  
Gene Expression ◽  
Macular Degeneration ◽  
Gene Expression Profile ◽  
Expression Profile ◽  
Age Related Macular Degeneration ◽  
Intravitreal Ranibizumab ◽  
Age Related
Sign in / Sign up

Export Citation Format

Share Document